David Coles
Interim Chief Executive Officer

David Coles was appointed Interim Chief Executive Officer in June 2018, and is a Managing Director with Alvarez & Marsal, a global professional services firm. Mr. Coles has more than 25 years’ financial and operational restructuring experience. He specializes in performance improvement and interim management for underperforming businesses and businesses in transition.

Mr. Coles has deep experience working with executive teams in senior advisory and interim C-suite roles. His experience spans both public and private companies in multiple industries with a recent focus being public companies in financial services and real estate. Most recently, Mr. Coles served as CRO of Walter Investment Management, Inc. (“WIMC”), a publicly-traded forward and reverse residential mortgage originator and servicer which confirmed a prepackaged plan of reorganization and emerged in February, 2018. As CRO, he coordinated restructuring activities including communications with key governmental (GSE, SEC) and commercial constituents.

Mr. Coles served as CEO of Campus Crest (“CCG”), a public REIT specializing in student housing (approximately 55,000 beds). CCG was the subject of an activist shareholder campaign and a financial restatement. The Company entered into a sale process and was ultimately sold in a take-private transaction.

He was CFO of PHH Corp., a public, non-troubled residential mortgage originator and servicer and vehicle fleet management business. At PHH, he assisted with internal and external financial reporting, capital raising, treasury operations (cash management, securitization, collateral management and investor reporting) rating agency and debt and equity investor communications. As financial advisor to Charter Behavioral Health System he supported the sale process for this behavioral health business and co-led (with the CEO) communications and settlement discussions with DHHS and DOJ. As CFO of Lehman Brothers Holdings Inc., he managed the initial crisis management and liquidity generation phases. Previously, Mr. Coles' assignments included Leiner Health Products Inc. where, as interim CFO/CRO, he managed the operational reengineering and financial restructuring of this vitamin, mineral and supplement business.

At NCFE, a healthcare receivable financing business, he became CEO/CRO following the filing of a bankruptcy petition as a result of the discovery of fraudulent activity. He coordinated communications with key governmental agencies such as DHHS and DOJ. As an adviser to the parent company, Mr. Coles led profitability improvement projects at three consumer businesses (Precor, West Bend and Florida Tile). At Shark|Ninja (fka Euro-Pro Holdings, Inc.), a $1 billion+ consumer products business, as CRO, he co-led its financial and operational restructuring. From negative EBITDA in 2006, the business was partially divested in 2017 at a valuation well in excess of $1bn. He had previously served as COO at Applica, a licensee of Black & Decker in the kitchen appliance space.

Prior to joining A&M in 1997, Mr. Coles was with the restructuring group of Arthur Andersen in New York, having transferred from its Birmingham, U.K. practice. Mr. Coles earned a bachelor's degree from the University of Wales Institute of Science & Technology in Cardiff, U.K. He has passed the examinations of the Institute of Chartered Accountants in England and Wales.

Edward J. Borkowski
Interim Chief Financial Officer

Mr. Borkowski, was appointed Interim Chief Financial Officer on June 6, 2018. He previously served as Executive Vice President of MiMedx since April 19, 2018. Prior to joining the Company, Mr. Borkowski served as the Chief Financial Officer of Aceto Corporation, an international company engaged in the development, marketing, sales and distribution of pharmaceutical products, from February 2018 until April 2018. Prior thereto, he held several executive level positions with Concordia International Corp., an international specialty pharmaceutical company, from 2015 to 2018, including serving as a Director, as Chief Financial Officer and as Executive Vice President. Previously, Mr. Borkowski served as Chief Financial Officer at Amerigen Pharmaceuticals, a privately-held pharmaceutical company focused on generic products, from 2013 to 2016 and ConvaTec Group PLC, an international medical products and technologies company, from 2012 to 2013. Mr. Borkowski serves as the Chairman of AzurRx BioPharma,Inc. and is on the Boards of Acacia Pharma Group PLC and Co-Diagnostics Inc..  He is also a Trustee of Allegheny College, where he serves on the Executive Committee and is Chairman of the Budget Committee.

He is a Member of the American Institute of Certified Public Accountants and the New York State Society of CPAs. Mr. Borkowski holds a Bachelor of Science in Economics and Political Science from Allegheny College and a Master in Business Administration in Finance and Accounting from Rutgers University.

Alexandra O. Haden
General Counsel and Secretary

Ms. Haden has served in the capacity of General Counsel & Secretary since March 1, 2015. Ms. Haden joined MiMedx in June 2013 in the capacity of Senior Attorney. She served in that role until her promotion to the position of Assistant General Counsel in April 2014, where she served until her current appointment. Ms. Haden has over 15 years’ experience as both in-house and outside corporate counsel. She has expertise in general corporate and commercial law, mergers & acquisitions, employment law, labor arbitrations, litigation management intellectual property law, regulatory compliance, and domestic and international logistics. Ms. Haden has experience advising executives on difficult legal matters and business risks and developing legal strategies to position companies in the most favorable position to achieve their business goals.

Immediately prior to joining MiMedx, Ms. Haden served as Assistant General Counsel at Graphic Packaging International, Inc., a $4.2 billion publicly traded provider of packaging solutions for a wide variety of products to food, beverage and other consumer products companies with some of the most widely recognized brands in the world. Prior thereto, Ms. Haden served with Consolidated Container Company, LLC, the leading developer and manufacturer of rigid plastic packaging solutions in North America, from May 2004 until April 2007.

Prior to Consolidated, Ms. Haden served as counsel with the Atlanta, Georgia law firm of Elarbee, Thompson, Sapp & Wilson, LLP. Ms. Haden specialized in the defense of employment cases, EEOC charges, conciliation processes, employment contracts, arbitration policies, and collective bargaining actions and activities.

In 1999, Ms. Haden received her Juris Doctorate and began her law career. She earned her bachelor’s degree in Public Policy from the University of Chicago in 1996 and her law degree from the University of North Carolina School of Law.

Christopher M. Cashman
EVP and Chief Commercialization Officer
Christopher M. Cashman joined MiMedx as the Company’s Executive Vice President & Chief Commercialization Officer in November 2014. In his role, Mr. Cashman will contribute his expertise to the Company’s global sales & marketing functions, strategic planning and all related revenue growth initiatives. Most recently, Mr. Cashman was President and Chief Executive Officer of SANUWAVE Health, a regenerative medicine company focused on the development and commercialization of Extracorporeal Shock Wave Technology for chronic wound care, orthopaedic, cardiovascular and plastic surgery. Before joining SANUWAVE, he served as President of Therapeutic Surfaces for Kinetic Concepts, Inc. (KCI), a worldwide leader in advanced wound healing products. Prior to that, Mr. Cashman was President and Chief Executive Officer for Snowden Pencer, a manufacturer of minimally invasive devices and specialty surgical instrumentation. He successfully led a management buyout of Snowden Pencer from Genzyme in 2001, and the business was sold in 2004 to Cardinal Health. Mr. Cashman also held various sales, marketing and general management positions within divisions of Genzyme Biosurgery and Deknatel. Following his graduation from the United States Naval Academy, Mr. Cashman served as Supply Officer on the USS Trepang, a fast attack nuclear submarine. Mr. Cashman is also an Industry Fellow and Advisor to the Georgia Research Alliance (GRA) where he guides and assists GRA Venture supported University research and early stage companies to aid in building successful businesses in the medical sciences and technology fields. He is also a Board Director for Bio/Med Investor Network. Mr. Cashman holds an MBA from Northwestern University’s Kellogg Graduate School of Management, and is a graduate of the United States Naval Academy, where he received a Bachelor’s of Science in Economics.
Deborah L. Dean
Executive Vice President

In July 2012, Ms. Dean joined MiMedx in the capacity of Vice President of Operational Systems. In October 2012, Ms. Dean was appointed Executive Vice President of MiMedx. Ms. Dean is an executive with C-Level expertise and experience in operations, general management, sales & marketing, business development, key account management, technology, data integration, analytics, applications development, informatics and technical infrastructure.

Prior to joining MiMedx, Ms. Dean was President & Chief Operating Officer of HolaDoctor, the Number One Hispanic Health Digital Site and exclusive partner to During her tenure with HolaDoctor, she played a key role in the transformation of the company from a primarily translation and research consulting company to a health information company delivering over 12 million digital impressions per month.

Immediately prior to her association with HolaDoctor, Ms. Dean served with Matria Healthcare from 2005 to 2008. She began her career with Matria in the capacity of Vice President of Information Technology with responsibility for all Technology applications development, database management and systems networking and infrastructure. In February 2008, she was appointed to the position of Executive Vice President and Chief Technology Officer for Matria Healthcare reporting directly to the Chairman & CEO. In this elevated role, she assumed the additional responsibilities for the Product Management and Informatics Departments where she led the massive data integration of all disparate health plan, employer, Pharmacy Benefit Manager, and Third Party Administration systems into the Company’s proprietary health wellness and disease management software. With her 15 years of healthcare expertise, Ms. Dean brought a proven process and development discipline to Matria Healthcare’s Technology organization. She engineered and enhanced the architecture for data processing infrastructure of this disease management and wellness company to become a core selling point and strength. Matria Healthcare was sold to Inverness Medical Innovations in May 2008 in a transaction valued at over $1.2 billion.

Prior to joining Matria, Ms. Dean was Senior Vice President of Research and Development and General Manager of the Provider Business for Quovadx, Inc., a leading healthcare integration company. While at Quovadx, she developed the premier eligibility and claims clearinghouse product that integrated the top clearinghouses such as HDX, WebMD, MedUnite, Proxymed and Medifax. Ms. Dean joined Quovadx via its acquisition of (Healthdyne Information Enterprises) where she held key data warehousing and client informatics reporting management roles. Prior thereto, she served with Medstat (acquired by Thomson Reuters) in numerous data warehousing and informatics roles.

Ms. Dean earned a bachelor’s degree in Health Services Administration from Arkansas State University.

Donald E. Fetterolf M.D.,FACP
Chief Medical Officer

Dr. Fetterolf currently serves as Chief Medical Officer of MiMedx Group. He began his association with MiMedx in July 2009. Initially, Dr. Fetterolf served as a consultant to the Company, and in June 2011, he increased his involvement with MiMedx in the role of part-time Vice President of Medical Affairs, and in October 2011, Dr. Fetterolf transitioned into his full time role of CMO.

Dr. Fetterolf is an experienced physician executive with extensive expertise in clinical medicine, health care business administration, medical informatics and the management and economics of complex health care organizations.

Before joining MiMedx, Dr. Fetterolf’s work experience included roles as Executive Vice President of Health Intelligence at Alere, Executive Vice President of Health Intelligence at Matria Healthcare, Chief Medical Officer of Highmark, Inc., President of the ALPHA Health Network in Pennsylvania, and President of Allegheny Intermed, a medical group practice.

These previous operating environments have included a major health plan, corporate disease management, medical practice, and hospital-physician joint venture (“PHO”) organizations. He has also delivered private consulting services for commercial and government accounts.

Dr Fetterolf was the first recipient of the Brian Hayes Award of the Blue Cross Blue Shield Association in 2004, created to honor the most outstanding medical director in the Blue Cross Blue Shield system. He was awarded the DMAA 2006 Disease Management Leadership Annual Award for Outstanding Individual Leadership. He was recognized in 2010 as a national thought leader by the Case Management Society of America (CMSA) in their Shining Lights edition of their journal. He is a Fellow in the American College of Physicians, the College of Physicians of Philadelphia, the American College of Physician Executives, and the Academy of Healthcare Management. Dr. Fetterolf is Past President of the American College of Medical Quality, where he is a Distinguished Fellow and is Secretary/Treasurer of the American Board of Medical Quality. He has served in the past on the Board of Directors of the Disease Management Association of American (DMAA), where he also directed a national effort to develop economic measures in disease management. He is on the editorial board of several journals including Population Health Management, the American Journal of Medical Quality, and Perspectives in Health Information Management.

Dr. Fetterolf received dual undergraduate degrees in Chemistry and Biochemistry and an M.D. degree from the University of Pennsylvania in Philadelphia. He completed an internship and residency in internal medicine at the University of Pittsburgh, and there also completed a Masters in Business Administration. Don is certified by the American Board of Internal Medicine, the American Board of Medical Quality and the American Board of Quality Assurance and Utilization Review Physicians.

Mark P. Graves
Chief Compliance Officer

Mr. Graves joined MiMedx in July 2018 and brings more than 20 years of pharmaceutical and biotech industry experience to the Company, ranging from compliance and sales management to government affairs. He most recently was the U.S. leader for the global Patient Experience & Value function in the neurology division of UCB, Inc., a biopharmaceutical company. From 2011 to 2015, he was UCB’s Deputy Compliance Officer involved in all aspects of compliance including the implementation and management of the company’s corporate integrity agreement. Prior to that, Graves was Senior Director in the Office of Ethics and Compliance for the Pharmaceutical Products Division of Abbott Laboratories, as well as Deputy Ethics & Compliance Officer for Takeda Pharmaceuticals North America, Inc. and TAP Pharmaceutical Products, Inc. Prior to his pharmaceutical and biotech career, he practiced labor and employment law.

Mr. Graves holds a B.A. in Criminology and Law, and a J.D. from the University of Florida as well as an MBA from the University of Chicago Booth School of Business.

Thomas J. Koob PhD
Chief Scientific Officer

Dr. Koob is the Chief Scientific Officer of MiMedx. He is the senior executive responsible for the overall research direction and oversight of the Company’s product and tissue offerings. Dr. Koob is the inventor on the patents related to the Company’s CollaFix™ technology that are the basis of the Company’s license agreement with Shriners Hospitals for Children and the University of South Florida. MiMedx was founded around the collagen technology developed by Dr. Koob.

Prior to MiMedx, Dr. Koob was Section Chief of Skeletal Biology at Shriners Hospital for Children in Tampa, Florida. During the fourteen years he held this position, Dr. Koob developed and patented the core technology for what would become the MiMedx CollaFix™ technology platform. Prior to his tenure with Shriners, Dr. Koob held various research appointments at institutions such as the Department of Biology at Boston University, Department of Biological Chemistry at Harvard Medical School, Department of Biology at the University of New Mexico, Department of Anatomy at the University of New Mexico School of Medicine, Orthopaedic Biomechanics Laboratory at Beth Israel Hospital, and Mount Desert Island Biological Laboratory.

Dr. Koob has published over 125 biomedical and biological articles and 12 book chapters, and he is listed as an inventor on over 40 issued and pending patents.

Dr. Koob received his Ph.D. in Biochemistry from Washington University School of Medicine in St. Louis, Missouri. He completed four years of post-doctoral training at Harvard Medical School and four years of specialty training in the Laboratory of Skeletal Disorders, Department of Orthopaedics at Children’s Hospital Medical Center in Boston.

Michael W. Carlton
Senior Vice President of Global Sales

Mr. Carlton joined MiMedx Group in November 2009 as the Company’s Vice President of Global Sales. In January 2014, Mr. Carlton was named Senior Vice President of Global Sales. With over 20 years of domestic and international medical device sales and sales management experience, Mr. Carlton leads the Company’s initiatives to broadly and effectively market its products and tissues.

Mr. Carlton has established the sales and marketing infrastructure to serve the unique sales and marketing needs created by Company’s products and tissues that are in high demand. He has assembled a direct sales force of highly seasoned sales professionals, regional management and national management with specialty and focus in the segments of advanced wound care, burns healing, soft tissue trauma, nerve and tendon repair, spinal applications, orthopedics and sports medicine. Complementing the direct sales force, Mr. Carlton has assembled and leads a specialized network of distributors and independent sales representatives.

Mr. Carlton’s most recent role prior to joining MiMedx Group was with Synthes Spine, where he was the Orthopedic Manager in Georgia. Prior to his role with Synthes Spine, Mr. Carlton was responsible for a national sales force with Abbott Vascular, a $600 million division of parent company, Abbott. He joined Abbott in 2000 and was responsible for all US commercial operations, marketing, and customer service with responsibility for 14 regions, and a sales force of 185 representatives. During his tenure with Abbott, Mr. Carlton last served as the National Director of their $160 million Coronary and Vascular Closure Divisions.

Before joining Abbott Vascular, he served for six years in multiple sales, training and sales management roles at Boston Scientific. Prior to Boston Scientific, Mr. Carlton began his sales career with Kendall Urologic and Wound Care Products where he served for four years in key account sales positions.

Mr. Carlton is a graduate of Miami University, Oxford Ohio with a B.A. in Marketing and attended Xavier University, Keller School of Management, in Cincinnati, Ohio for course work toward an MBA.

Marlene M. DeSimone
Senior Vice President of Marketing

Since joining MiMedx in November 2013, Ms. DeSimone has served as Senior Vice President of Marketing. She was instrumental in the development of the MiMedx Corporate Strategic Plan which defines the framework for the Company’s corporate growth over the next five years. Ms. DeSimone facilitated the collaboration among the Company’s executives and its Board of Directors to produce this important plan for the Company’s future growth. In addition, Ms. DeSimone is responsible for providing executive leadership and management of the Company’s marketing organization to position MiMedx as the leader across the Company’s portfolio of products and various markets.

Immediately prior to joining MiMedx, Ms. DeSimone was a Managing Partner of Velocity P3, a specialized solutions consulting firm providing services to the healthcare industry. Ms. DeSimone was a co-founder of Velocity P3 which was focused on commercialization strategies, business/leadership acceleration, and patient adherence support. Prior to forming Velocity P3, Ms. DeSimone served with Matria Healthcare from 2004 through 2009. She was the Senior Vice President of Business Development at Matria, and in that role, she built Matria’s biopharmaceutical business focused on patient adherence activities. In addition, she led the sales organization for the employer and health plan verticals where revenues were in excess of $350 million. Ms. DeSimone left Matria one year after its sale to Inverness to start Velocity P3.

Prior to Matria, Ms. DeSimone held various and increasingly more responsible, sales, marketing and new business development positions with leading biopharmaceutical companies. With Dendrite International/SYNAVANT Inc., she served in the role of Vice President, Global Strategic Solutions; with, she held the position of Vice President, Business Development; and with Schering-Plough Corporation, she served as Product Director, Marketing for the BioOncology franchise, Oncology District Manager, National Account Manager, Sales Operations Manager and Sales Representative. Ms. DeSimone began her career as a Registered Nurse with George Washington University Medical Center before moving into medical sales with Bialek Corporation.

Ms. DeSimone earned her Bachelor of Science in Nursing from The American University in Washington, D.C. She is a Foundation Associate of the Women Business Leaders/U.S. Healthcare Industry Foundation, a member of the Healthcare Marketing & Communications Council and the Healthcare Businesswoman’s Association where she served on its Board of Directors from 2004-2006.

John D. Harris
Senior Vice President, International

With 20+ years of experience in the regenerative medicine, medical device and cell therapy fields, John D. Harris joined MiMedx as Senior Vice President, International in June 2018. In this role, Mr. Harris leads MiMedx’s strategic expansion into key international markets.

Most recently, Mr. Harris served for two and a half years as Vice President & General Manager at Cytori Therapeutics, a pioneer in autologous adipose derived cell therapy. In this role, Mr. Harris was a named executive officer (NEO) with full responsibility for the global P&L and managed various functions within the company including its wholly owned subsidiary in Japan. Mr. Harris was actively engaged with investors, analysts & partners individually as well as participating in quarterly earnings calls. Prior to Cytori, Mr. Harris spent six years at Becton Dickinson’s Japan entity, and as the country CEO, he led an organization of over 600 employees, including a manufacturing & logistics center and a P&L in excess of $300M. He was a recognized leader during his time at BD, and served as a member of the Global BD Leadership Team and the BD Greater Asia Leadership Team. Mr. Harris was actively engaged externally, in elected leadership positions with the American Chamber of Commerce in Japan (ACCJ) and the American Medical Device & Diagnostics industry association (AMDD).

Mr. Harris’s background also includes global & regional leadership roles in product development, sales, marketing and market development with TE Connectivity, Delphi Medical Systems and Ballard Medical/Kimberly-Clark Healthcare (now Halyard Health). Mr. Harris is fluent in Japanese and received his BA and MBA from the University of Utah.

Thornton Kuntz
Senior Vice President of Administration

In October 2009, Mr. Kuntz began his association with MiMedx Group, Inc. providing advisory services to the Company. Initially, Mr. Kuntz provided his services to MiMedx through his human resources advisory solutions business, Austin Consulting Group, LLC. In January 2010, his services were expanded to include serving MiMedx in the position of Vice President of Human Resources & Administration on a part-time basis. In April 2014, Mr. Kuntz was named Senior Vice President of Administration and currently serves in that capacity.

Mr. Kuntz brings 35 years of C-level expertise in learning & development, safety management, talent management & acquisition, process design, change management, strategic planning, organizational alignment, mergers & acquisitions, executive & Board compensation, corporate administration, succession planning, external/internal communications and public reporting. He has successfully led talent management processes and learning & development initiatives to strategically transition companies into dominant market leaders, facilitated organizational re-design to produce prolific growth, successfully assimilated more than 35 acquisitions, created “corporate university” curriculums to support aggressive initiatives for clinical, technology, operations, sales and general management, and led the succession and career planning initiatives for executive talent. During his career, Mr. Kuntz has received numerous awards for excellence in public company annual reports.

Mr. Kuntz served with Alere f/k/a Matria Healthcare, Inc. f/k/a Healthdyne, Inc. from 1992 until 2008. From 2008 to 2009, Mr. Kuntz served as Executive Vice President of Culture & Performance for Alere, a subsidiary of Inverness Medical Innovations, Inc. which acquired Matria Healthcare in 2008. Mr. Kuntz served Matria as Senior Vice President and Chief Administrative Officer from 2006 to 2008, as Vice President of Administration from 1998 until 2006, and as Vice President of Human Resources from the 1996 formation of Matria Healthcare (the merger of Healthdyne Maternity Management and Tokos Medical Corporation) until 1998. Mr. Kuntz joined Healthdyne, Inc., the predecessor company to Matria Healthcare , in 1992 and served as Vice President of Administration until the merger in 1996.

Prior to joining Healthdyne, Mr. Kuntz was associated with Glasrock Home Health Care, Inc. from 1985 to 1992, where he served as Vice President of Human Resources from 1989 to 1992 and as Director of Human Resources Administration from 1985 until 1989. Mr. Kuntz was associated with The Louisiana Land and Exploration Company from 1977 to 1985 in various human resources positions including Manager of Employee Relations from 1980 to 1985. Mr. Kuntz served as a Human Resources Representative with the Ocean Drilling and Exploration Co. from 1975 to 1977.

Mr. Kuntz earned a bachelor’s degree in management from the University of New Orleans in 1975.

Dr. I. Mark Landy
Senior Vice President Strategic Initiatives

Dr. Landy joined MiMedx in June 2016 as the Company’s Vice President of Strategic Initiatives. Reporting to the Chairman & CEO, Dr. Landy fulfills multiple responsibilities supporting key strategic initiatives involving various investor relations activities, the Company’s domestic and international strategic and related growth initiatives, strategic and tactical planning and other critical initiatives.

Dr. Landy’s wide array of experience includes holding senior roles in institutional healthcare equity research, Portfolio Management and C-Level executive roles in the drug delivery and medical devices sectors of the healthcare industry. He has over fifteen years of Wall Street expertise and seven years of healthcare industry experience.

Immediately prior to joining MiMedx, Dr. Landy was Director of Research, Managing Director and Senior Research Analyst – Biopharmaceuticals and Medical Technology at Northland Capital Markets / Summer Street Research Partners. Prior thereto, Dr. Landy served with MIV Therapeutics, Inc., a global leader in developing polymer-free drug delivery systems for cardiovascular stents and other implantable devices. During his time at MIV, Dr. Landy served as a Director of the company, President and Chief Executive Officer. Prior to his tenure with MIV, he held senior positions with Susquehanna Financial Group; Leerink; Merlin BioMed Capital Management; and Investor AB.

Dr. Landy holds a Bachelor of Business Administration from The Wharton School of Business, University of Pennsylvania, and a Doctor of Dental Surgery from the University of the Witwatersrand, Johannesburg, South Africa.

Gloria Matthews, DVM, PhD, DACVS
Senior Vice President, Research and Development

Dr. Matthews joined MiMedx in October, 2017 as Senior Vice President of Research and Development.

Dr. Matthews is a surgeon-scientist with two decades of experience in biomedical innovation and product pipeline development and support, including programs from Discovery through Phase III Clinical Development for devices, orthobiologics, combination products, and new chemical entities for osteoarthritis, cartilage repair, and regenerative medicine. She brings a strong executive track record of leveraging cross-functional teams in conjunction with talented Research and Development groups to build and help advance organizations to the next level, establishing new institutional paradigms and introducing effective strategic initiatives that incorporate Research and Development in mutually beneficial ways into all aspects of Operations.

Most recently, Dr. Matthews served as Chief Medical Officer at Histogenics, a Boston-based regenerative medicine company at which she was responsible for all Clinical, Clinical Operations, and Medical Affairs activities with strategic oversight of both North American and global development programs. She provided cell therapy and biologics Regulatory consultation in this role, directly supported all Business/Corporate Development efforts, and actively participated in successful corporate fundraising for this publicly traded pre-revenue stage company.

Prior to Histogenics, Dr. Matthews spent 12+ years in the biopharmaceutical industry at Genzyme Corporation and Sanofi-Genzyme, providing Research and Development support to the Biosurgery business. During her tenure at Genzyme, she oversaw Clinical and Preclinical Development and post-market support of cell, gene, growth factor, small molecule and biomaterial based products in the orthopedic, rheumatologic, and renal space. Dr. Matthews last served with Sanofi-Genzyme in the role of Senior Director and Global Head of Bone and Joint Disease Research and Development.

Dr. Matthews received both her DVM and Ph.D. degrees from Cornell University, completing her residency training in surgery at Tufts, and fellowship training at Cornell. She received her Ph.D. in cell and molecular biology, with a focus in joint development and osteoarthritis. Dr. Matthews is the incoming President of the Orthopaedic Research Society, a member of the Cornell University Biomedical Engineering Advisory Board, and sits on the American Academy of Orthopaedic Surgeons Board of Orthopaedic Specialties.

Rebeccah J. C. Brown Ph.D.
Vice President of Product Development

Dr. Brown joined SpineMedica LLC, an early-stage predecessor company to MiMedx, in 2005. She initially served as the Director of Project Management and Senior Engineer for SpineMedica, and later served as its Director of Research and Development and as Vice President of Operations. In those roles, she was instrumental in the development and launch of the Company’s HydroFix® technology. Since the Company’s inception, Dr. Brown was been leading the Company’s product development efforts, including growing and managing the intellectual property portfolio. Following the combination of SpineMedica with MiMedx, Inc. in 2007, Dr. Brown has served as the Company’s senior executive responsible for Product Development. In April 2013, Dr. Brown was named Vice President of Product Development, Regulatory Affairs and Quality Assurance.

Dr. Brown has over twenty years of experience leading teams to produce innovative and impactful products. She has worked at companies ranging in size from 12 employees to 120,000, and has an impressive track record for integrating customer needs with company goals.

Before joining SpineMedica, Dr. Brown worked as Project Manager and Staff Engineer at SaluMedica, LLC, a medical device company pioneering the development of devices to replace soft tissue throughout the body. While a graduate student at the Georgia Institute of Technology where her research focused on the durability of orthopedic implants, Dr. Brown also worked with SaluMedica, as well as Oak Ridge National Laboratory and Advanced Tissue Sciences. Dr. Brown designed and fabricated mechanical testing systems to evaluate the durability of cartilage and cartilage prostheses.

Dr. Brown has also worked at Centerpulse (formerly Sulzer Medica) in Winterthur, Switzerland as a Research Engineer where she investigated xenograph amd tissue engineering options for articular cartilage repair and treatment. Before Centerpulse, Dr. Brown worked as a Product/Process Engineer at Hewlett-Packard.

Dr. Brown holds a Ph.D. and M.S. from the Georgia Institute of Technology, where she was a National Science Foundation Graduate Research Fellow, and a B.S. in Mechanical Engineering from the Massachusetts Institute of Technology.

Frank Burrows
Vice President Clinical and Scientific Liaison

Mr. Burrows joined MiMedx Group in April 2011 as Vice President of Wound Care to lead the marketing of the Company’s wound care offerings and other exciting products and tissues. He assumed the role Of Vice President of Global Marketing in August 2011 to focus on expanding the Company’s presence in the regenerative tissue market. In October 2012, Mr. Burrows was appointed to the position of Vice President of Corporate Strategy. He has brought to MiMedx over 20 years of experience and expertise in developing and implementing sales and marketing plans that have created prolific growth for numerous medical devices and pharmaceuticals. In March 2014, Mr. Burrows was named Vice President of Clinical and Scientific Liaison.

Mr. Burrows has held positions with notable companies like Johnson & Johnson, Smith & Nephew, W.L. Gore and CryoLife. In Mr. Burrow’s 20-year career, he has amassed a track record for successfully developing and implementing strategic and tactical marketing plans to launch and grow medical devices, human tissue, and pharmaceuticals in the areas of tissue engineering; regenerative medicine; wound closure and healing; growth factor therapy; cardiothoracic, vascular, endovascular surgery; diabetes; women’s health; anesthesia; heart disease; biologics; and bio-active therapeutics.

Mr. Burrows’ most recent role prior to joining MiMedx Group was with CryoLife, Inc., where he served as Director of Marketing and had responsibility for development and execution of marketing plans for allograft tissues for uses in aortic, pulmonary and vascular procedures. Before his tenure with CryoLife, he was Director of Sales & Marketing for Histogen Aesthetics, a startup biotechnology company in the regenerative medicine market. Prior thereto, he was Marketing Director for W.L. Gore from 2006 to 2008 and had responsibility for leading their global marketing efforts in the Abdominal, Aortic and Aneurysm (AAA) endovascular market segment.

From 2001 to 2006, Mr. Burrows served with J&J Wound Management Company, a division of ETHICON, as Director of Professional Education from 2004 to 2006 and as Sr. Product Director from 2001 to 2004. With J&J, he successfully revitalized and re-launched their brand in the highly differentiated and competitive advanced wound care market and directed their formal education programs to drive scientific and clinical utilization rationale. From 1999 to 2000, Mr. Burrows served as Vice President of Adient and directed its account teams serving key accounts such as Bristol-Myers Squibb and Ortho-McNeil. He served as Marketing Manager, Acute Care with Smith & Nephew from 1997 to 1999 focusing on their acute care products and supporting the launch of the Company’s novel biotechnology and advanced wound care products. In 1991, Mr. Burrows began his career with Advanced Tissue Sciences, where he held numerous marketing and business development roles.

Mr. Burrows holds degrees in Marketing from Point Loma Nazarene University and an MBA in Marketing & Advertising from University of La Verne. Mr. Burrows received his EMT from Saint Michael’s Medical Center.

David H. Mason, Jr., M.D.
Vice President of Medical Affairs for Clinical Practice

Dr. Mason joined MiMedx in June 2014, in the position of Vice President of Medical Affairs for Clinical Programs. Dr. Mason is a Board Certified Internist, board eligible in Rheumatology and Infectious Diseases, whose experience includes a 27-year pharmaceutical and medical device industry career, with increasing levels of responsibility. His experience covers multiple therapeutic areas and includes management of Clinical Development and Medical Affairs groups; Regulatory Affairs including QA; Public Affairs, Public Policy and Public Relations. Dr. Mason has extensive experience in all phases of drug development including preclinical, regulatory and clinical trials from Phases I through IV. His vast experience includes handling IND filings, protocol writing, more than ten successful BLA and NDA submissions, multiple successful 510(k) and de novo device clearances, and a similar number of drug and device product launches.

Before joining MiMedx, Dr. Mason previously served as Senior Vice President and Chief Medical Officer of Given Imaging where he led clinical trials, regulatory affairs and medical marketing initiatives. Before joining Given, Dr. Mason served with UCB Pharma as the company’s Vice President, Clinical Development and Global Head of Inflammation Clinical Research. In this role, Dr. Mason led the U.S. and U.K. teams in support of the regulatory pathways for the company’s portfolio of anti-inflammatory drugs. Dr. Mason also served with AVI BioPharma as its Senior Vice President of Clinical Development and Regulatory Affairs where he led drug development efforts including clinical programs in multiple therapeutic areas.

After medical school, Dr. Mason pursued a 15 year career in medical practice in both academic and private practice settings. During this time, Dr. Mason was a practicing physician in internal medicine, infectious diseases and rheumatology. Following his tenure in medical practice, Dr. Mason began his pharmaceutical and medical device industry career by joining Ciba-Geigy Pharmaceuticals in the capacity of Director, Clinical Research and Executive Director, Medical Affairs.

Dr. Mason has authored more than 15 manuscripts on clinical studies that have been published in peer-reviewed literature. He has authored a textbook article and a number of clinical abstracts that have been published in peer-reviewed journals.

Dr. Mason received his M.D. from Duke University Medical School. He earned a BA in Chemistry from Williams College. He completed an internship and fellowship in Rheumatology at Duke University Hospital and completed his residency in Internal Medicine at the University of Michigan Medical Center. Dr. Mason has also served as a Research Associate and USPHS SA Surgeon (Lt. Comm.) at NIH, NIAID, Laboratory of Viral Diseases, Bethesda, Maryland.

Randall Spencer
Vice President of Clinical Innovation

Mr. Spencer is the co-founder of Surgical Biologics, a leading processor of amnion tissue for use in a variety of surgical implants. Since the founding of Surgical Biologics in 2006, he led the development of the proprietary PURION® Process, which processes human amniotic membrane to produce a safe, effective and minimally manipulated implant for homologous use. He has been a pioneer in the development of the latest advances in processing amniotic membrane tissue. MiMedx® acquired Surgical Biologics in January 2011, and Mr. Spencer served as the Company’s Director of Product Development until March 2013, when he assumed the role of Vice President of Clinical Innovation.

Mr. Spencer has been in the bioimplant industry since its infancy, with over 23 years of experience. He is an industry expert in the development of new products and new surgical treatments using bioimplant materials. Throughout his career, Mr. Spencer has made significant contributions to the development of a wide range of products which are now considered the standard of care for certain surgical procedures.

Before founding Surgical Biologics, he was Product Manager Bone Biopsy Division at InterV Medical Device Technologies. Prior to InterV, Mr. Spencer was Product Manager Regenerative Products at Tutogen Medical, where he designed products used in spinal and dental surgeries. Before joining Tutogen, he was with Regeneration Technologies, where Mr. Spencer created products that are used in spinal, sports medicine and orthopedic surgeries. Earlier in his career, Mr. Spencer worked for Johns Hopkins University as a researcher.

Mr. Spencer earned a Bachelors of Science degree in Health Science from Grand Valley State University.